Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer
Elizabeth P. Newberry, Zoe Hall, Yan Xie, et al.
Hepatology (2021) Vol. 74, Iss. 3, pp. 1203-1219
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 256
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Agnieszka Karkucińska‐Więckowska, Inês C. M. Simões, Piotr Kalinowski, et al.
European Journal of Clinical Investigation (2021) Vol. 52, Iss. 3
Open Access | Times Cited: 108
PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein
S. M. Johnson, Hanmei Bao, Cailin E. McMahon, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 29
VLDL Biogenesis and Secretion: It Takes a Village
Willemien van Zwol, Bart van de Sluis, Henry N. Ginsberg, et al.
Circulation Research (2024) Vol. 134, Iss. 2, pp. 226-244
Open Access | Times Cited: 22
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease
Fei Luo, Federico Oldoni, Avash Das
Hepatology Communications (2021) Vol. 6, Iss. 3, pp. 448-460
Open Access | Times Cited: 91
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD
Sílvia Vilarinho, Veeral Ajmera, Melanie Zheng, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 2241-2250
Open Access | Times Cited: 66
Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats
Fei Luo, Ēriks Šmagris, Sarah A. Martin, et al.
Cellular and Molecular Gastroenterology and Hepatology (2021) Vol. 13, Iss. 3, pp. 879-899
Open Access | Times Cited: 66
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
Christina‐Maria Flessa, Narjes Nasiri‐Ansari, Ioannis Kyrou, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15791-15791
Open Access | Times Cited: 66
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Jih-Kai Huang, Hsiang‐Chun Lee
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4300-4300
Open Access | Times Cited: 57
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Ibon Martínez-Arránz, Chiara Bruzzone, Mazen Noureddin, et al.
Hepatology (2022) Vol. 76, Iss. 4, pp. 1121-1134
Open Access | Times Cited: 49
Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis
Xiaoxiao Jiang, Sam Fulte, Fengyan Deng, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 619-631
Open Access | Times Cited: 49
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
Tingyu Fang, Hua Wang, Xiaoyue Pan, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 15, pp. 5681-5697
Open Access | Times Cited: 42
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
Claudia Campani, Jessica Zucman‐Rossi, Jean–Charles Nault
Cancers (2023) Vol. 15, Iss. 3, pp. 817-817
Open Access | Times Cited: 26
Advances in the genetics of nonalcoholic fatty liver disease
Veeral Ajmera, Rohit Loomba
Current Opinion in Gastroenterology (2023) Vol. 39, Iss. 3, pp. 150-155
Open Access | Times Cited: 25
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Maria Eva Argenziano, Mi Na Kim, Michele Montori, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 922-940
Closed Access | Times Cited: 12
From MASH to HCC: the role of Gas6/TAM receptors
Daria Apostolo, Luciana Louzada Ferreira, Federica Vincenzi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application
Vincent Chen, Graham F. Brady
Hepatology Communications (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut–liver axis
Xiang Zhang, Harry Cheuk-Hay Lau, Suki Ha, et al.
Nature Metabolism (2025)
Open Access | Times Cited: 1
Genetic variation inTERTmodifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
Stephan Buch, Hamish Innes, Philipp Lutz, et al.
Gut (2022) Vol. 72, Iss. 2, pp. 381-391
Open Access | Times Cited: 34
Conditional hepatocyte ablation of PDIA1 uncovers indispensable roles in both APOB and MTTP folding to support VLDL secretion
Zhouji Chen, Shiyu Wang, Anita Pottekat, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101874-101874
Open Access | Times Cited: 8
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism
Jing Liu, Henry N. Ginsberg, Gissette Reyes‐Soffer
Current Opinion in Lipidology (2024) Vol. 35, Iss. 3, pp. 157-161
Open Access | Times Cited: 8
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Yansong Fu, Zhipeng Wang, Hong Qin
Metabolites (2024) Vol. 14, Iss. 4, pp. 218-218
Open Access | Times Cited: 8
Update on genetics and epigenetics in metabolic associated fatty liver disease
Xiaopeng Zhu, Mingfeng Xia, Xin Gao
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 25
Novel insights into metabolic‐associated steatotic liver disease preclinical models
Rocío Montero‐Vallejo, Douglas Maya‐Miles, Javier Ampuero, et al.
Liver International (2024) Vol. 44, Iss. 3, pp. 644-662
Open Access | Times Cited: 5
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Manuela Vitulo, Elisa Gnodi, Giulia Rosini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12748-12748
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top